New Delhi: Monoclonal antibody cocktail, used for the treatment of COVID-19, is unlikely to lead to further mutation of the virus, said Dr Raman R Gangakhedkar, former Head Scientist of Epidemiology and Communicable Diseases at the Indian Council of Medical Research (ICMR) on Sunday.Speaking to ANI, Gangakhedkar also said that when a person develops moderate to severe illness, it's more likely due to a dysregulated immune response rather than the virus itself."I don't think that it will lead to mutation theory-wise because we know when the person develops moderate to severe illness we also know that it's more likely due to dysregulated immunity response rather than the virus itself.
Read more on livemint.com